Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $1.1 million.

  • Avidity Biosciences' Depreciation & Amortization (CF) rose 57.14% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 31.04%. This contributed to the annual value of $2.8 million for FY2024, which is 33.27% up from last year.
  • Per Avidity Biosciences' latest filing, its Depreciation & Amortization (CF) stood at $1.1 million for Q3 2025, which was up 37.50% from $800,000 recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Depreciation & Amortization (CF) registered a high of $1.1 million during Q3 2025, and its lowest value of $100,000 during Q2 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $700,000 (2024), whereas its average is $691,273.
  • Data for Avidity Biosciences' Depreciation & Amortization (CF) shows a peak YoY spiked of 200.00% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Depreciation & Amortization (CF) stood at $208,000 in 2021, then soared by 89.42% to $394,000 in 2022, then skyrocketed by 52.54% to $601,000 in 2023, then climbed by 26.79% to $762,000 in 2024, then spiked by 57.14% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $800,000 for Q2 2025, and $800,000 during Q1 2025.